肝硬化腹水患者的螺内酯利尿作用
Spironolactone diuresis in patients with cirrhosis and ascites.
作者信息
Eggert R C
出版信息
Br Med J. 1970 Nov 14;4(5732):401-3. doi: 10.1136/bmj.4.5732.401.
Abstract
Increased aldosterone levels with consequent or diuretic-potentiated electrolyte abnormalities are an important consideration when patients with cirrhosis and ascites undergo diuresis. A simple clinical method using the urinary Na/K ratio as a guide to spironolactone dosage is outlined. Patients with a ratio greater than 1 responded well to 100 mg. of spironolactone a day; those when it was one or less responded well to 200 to 1,000 mg. a day.Administration of spironolactone alone (11 patients) or as the main diuretic (three patients) was a safe and effective means of inducing sustained uncomplicated diuresis in all these patients.
摘要
当肝硬化腹水患者进行利尿治疗时，醛固酮水平升高以及随之而来的或利尿剂增强的电解质异常是一个重要的考虑因素。本文概述了一种以尿钠/钾比值为指导来确定螺内酯剂量的简单临床方法。尿钠/钾比值大于1的患者，每天服用100毫克螺内酯反应良好；比值为1或更低的患者，每天服用200至1000毫克反应良好。单独使用螺内酯（11例患者）或作为主要利尿剂（3例患者）对所有这些患者来说都是诱导持续无并发症利尿的安全有效方法。
相似文献
1
Spironolactone diuresis in patients with cirrhosis and ascites.肝硬化腹水患者的螺内酯利尿作用
Br Med J. 1970 Nov 14;4(5732):401-3. doi: 10.1136/bmj.4.5732.401.
2
Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.速尿与螺内酯治疗非氮质血症性肝硬化腹水疗效的随机对照研究。利尿反应与肾素-醛固酮系统活性之间的关系。
Gastroenterology. 1983 May;84(5 Pt 1):961-8.
3
Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.新型袢利尿剂吡咯他尼在肝硬化腹水患者中的应用：利尿反应与血浆醛固酮水平的关系
Gut. 1980 Oct;21(10):855-9. doi: 10.1136/gut.21.10.855.
4
A randomized comparison of metoclopramide and domperidone on plasma aldosterone concentration and on spironolactone-induced diuresis in ascitic cirrhotic patients.甲氧氯普胺与多潘立酮对腹水型肝硬化患者血浆醛固酮浓度及螺内酯诱导利尿作用的随机对照研究。
Hepatology. 1985 Sep-Oct;5(5):854-7. doi: 10.1002/hep.1840050524.
5
Efficacy of low-dose captopril in addition to furosemide and spironolactone in patients with decompensated liver disease during blunted diuresis.在利尿反应减弱的失代偿性肝病患者中，低剂量卡托普利联合呋塞米和螺内酯的疗效。
J Hepatol. 1992 May;15(1-2):40-7. doi: 10.1016/0168-8278(92)90009-e.
6
Hyperkalemic changes during spironolactone therapy for cirrhosis and ascites, with special reference to hyperkalemic intermittent paralysis.
J Am Geriatr Soc. 1968 Aug;16(8):874-86. doi: 10.1111/j.1532-5415.1968.tb02682.x.
7
Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites.血浆醛固酮浓度对肝硬化腹水患者螺内酯利钠作用的重要性。
Digestion. 1985;31(4):189-93. doi: 10.1159/000199198.
8
Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion.通过预处理分数钠排泄预测肝硬化腹水的利尿剂动员
Klin Wochenschr. 1990 Jun 5;68(11):545-51. doi: 10.1007/BF01667146.
9
Metolazone and spironolactone in cirrhosis and the nephrotic syndrome.美托拉宗与螺内酯用于肝硬化及肾病综合征的治疗
Clin Pharmacol Ther. 1977 Feb;21(2):234-43. doi: 10.1002/cpt1977212234.
10
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.螺内酯单用或与呋塞米联用治疗非氮质血症性肝硬化中度腹水：一项疗效与安全性的随机对照研究
J Hepatol. 2003 Aug;39(2):187-92. doi: 10.1016/s0168-8278(03)00188-0.
引用本文的文献
1
Management of cirrhotic ascites.肝硬化腹水的管理
Ther Adv Chronic Dis. 2015 May;6(3):124-37. doi: 10.1177/2040622315580069.
2
Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy.治疗矿物ocorticoid 受体拮抗剂治疗引起的高钾血症。
Nat Rev Nephrol. 2012 Dec;8(12):691-9. doi: 10.1038/nrneph.2012.217. Epub 2012 Oct 16.
3
Guidelines on the management of ascites in cirrhosis.肝硬化腹水管理指南
Gut. 2006 Oct;55 Suppl 6(Suppl 6):vi1-12. doi: 10.1136/gut.2006.099580.
4
Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level.新型袢利尿剂吡咯他尼在肝硬化腹水患者中的应用：利尿反应与血浆醛固酮水平的关系
Gut. 1980 Oct;21(10):855-9. doi: 10.1136/gut.21.10.855.
5
The kidney and liver diseases.肾脏和肝脏疾病。
J Clin Pathol. 1981 Nov;34(11):1241-4. doi: 10.1136/jcp.34.11.1241.
6
Renin-angiotensin-aldosterone system in cirrhosis.肝硬化中的肾素-血管紧张素-醛固酮系统
Gut. 1980 Jun;21(6):545-54. doi: 10.1136/gut.21.6.545.
7
The hepatorenal syndrome revisited.
Intensive Care Med. 1987;13(3):145-7. doi: 10.1007/BF00254696.
8
Clinical and hormonal conditions associated with sodium retention in cirrhotic patients with ascites. Evaluation by univariate and multivariate analyses.肝硬化腹水患者钠潴留相关的临床和激素状况。单因素和多因素分析评估
Dig Dis Sci. 1987 Jun;32(6):569-76. doi: 10.1007/BF01296155.
9
Pathogenesis of ascites and hepatorenal syndrome.腹水和肝肾综合征的发病机制。
Gut. 1991 Sep;Suppl(Suppl):S12-7. doi: 10.1136/gut.32.suppl.s12.
10
Pharmacotherapy of ascites associated with cirrhosis.肝硬化相关腹水的药物治疗。
Drugs. 1992 Mar;43(3):316-32. doi: 10.2165/00003495-199243030-00003.
本文引用的文献
1
PROLONGED INFUSIONS OF ANGIOTENSIN II AND NOREPINEPHRINE AND BLOOD PRESSURE, ELECTROLYTE BALANCE, AND ALDOSTERONE AND CORTISOL SECRETION IN NORMAL MAN AND IN CIRRHOSIS WITH ASCITES.正常人和肝硬化腹水患者中血管紧张素II与去甲肾上腺素的长时间输注以及血压、电解质平衡、醛固酮和皮质醇分泌情况
J Clin Invest. 1965 Jul;44(7):1171-86. doi: 10.1172/JCI105224.
2
BODY AND SERUM POTASSIUM IN LIVER DISEASE. I. RELATIONSHIP TO HEPATIC FUNCTION AND ASSOCIATED FACTORS.肝病患者体内及血清中的钾。I. 与肝功能及相关因素的关系
Gastroenterology. 1965 Feb;48:198-207.
3
Human assay of electrolyte-active steroids and their antagonists.电解质活性类固醇及其拮抗剂的人体检测。
Clin Sci. 1962 Oct;23:197-202.
4
Significance of aldosterone antagonism in the treatment of edema and ascites.醛固酮拮抗在水肿和腹水治疗中的意义。
Am J Med. 1962 Oct;33:490-500. doi: 10.1016/0002-9343(62)90260-7.
5
The metabolism of aldosterone in normal subjects and in patients with hepatic cirrhosis.正常受试者及肝硬化患者体内醛固酮的代谢
J Clin Invest. 1962 Aug;41(8):1672-80. doi: 10.1172/JCI104624.
6
A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.氯噻嗪、螺内酯及二者联合作为利尿剂的性质比较。
N Engl J Med. 1961 Aug 24;265:358-62. doi: 10.1056/NEJM196108242650802.
7
Exchangeable potassium in wasting, amyotrophy, heart-disease, and cirrhosis of the liver.
Lancet. 1961 Apr 1;1(7179):681-7. doi: 10.1016/s0140-6736(61)91719-6.
8
Sodium diuresis induced by steroidal antagonists of aldosterone.醛固酮甾体拮抗剂诱导的钠利尿作用。
Science. 1957 Nov 15;126(3281):1016-8. doi: 10.1126/science.126.3281.1016.
9
Electrolyte excretion during the spontaneous recovery from the ascitic phase of cirrhosis of the liver.肝硬化腹水期自然恢复过程中的电解质排泄
Am J Med. 1967 Mar;42(3):359-67. doi: 10.1016/0002-9343(67)90264-1.
10
Zotero 插件